419 related articles for article (PubMed ID: 29202869)
1. Prognostic significance of hepatocyte growth factor activator inhibitor type 1 (HAI-1) immunoreactivity in pancreatic ductal adenocarcinoma.
Sakugawa C; Haruyama Y; Tanaka H; Fukushima T; Kawaguchi M; Kataoka H
BMC Res Notes; 2017 Dec; 10(1):674. PubMed ID: 29202869
[TBL] [Abstract][Full Text] [Related]
2. Expression of urocortin in pancreatic ductal adenocarcinoma and pancreatic intraepithelial neoplasia.
Cheng MF; Tsai WC; Hsia KT; Yang YS; Jin JS
APMIS; 2014 Feb; 122(2):147-54. PubMed ID: 23755913
[TBL] [Abstract][Full Text] [Related]
3. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
Shinkai K; Nakano K; Cui L; Mizuuchi Y; Onishi H; Oda Y; Obika S; Tanaka M; Katano M
Int J Cancer; 2016 Jul; 139(2):433-45. PubMed ID: 26939718
[TBL] [Abstract][Full Text] [Related]
4. Expression of SNAIL in accompanying PanIN is a key prognostic indicator in pancreatic ductal adenocarcinomas.
Fujiwara S; Saiki Y; Ishizawa K; Fukushige S; Yamanaka M; Sato M; Ishida M; Motoi F; Unno M; Horii A
Cancer Med; 2019 Apr; 8(4):1671-1678. PubMed ID: 30791220
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cells.
Fukushima T; Kawaguchi M; Yamasaki M; Tanaka H; Yorita K; Kataoka H
Cancer Sci; 2011 Feb; 102(2):407-13. PubMed ID: 21166957
[TBL] [Abstract][Full Text] [Related]
6. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.
Motoda N; Matsuda Y; Onda M; Ishiwata T; Uchida E; Naito Z
Int J Oncol; 2011 Jan; 38(1):133-43. PubMed ID: 21109934
[TBL] [Abstract][Full Text] [Related]
8. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
9. Nectin-1 expression in cancer-associated fibroblasts is a predictor of poor prognosis for pancreatic ductal adenocarcinoma.
Yamada M; Hirabayashi K; Kawanishi A; Hadano A; Takanashi Y; Izumi H; Kawaguchi Y; Mine T; Nakamura N; Nakagohri T
Surg Today; 2018 May; 48(5):510-516. PubMed ID: 29256146
[TBL] [Abstract][Full Text] [Related]
10. Integrated expression profiling of potassium channels identifys KCNN4 as a prognostic biomarker of pancreatic cancer.
Jiang S; Zhu L; Yang J; Hu L; Gu J; Xing X; Sun Y; Zhang Z
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):113-119. PubMed ID: 29050937
[TBL] [Abstract][Full Text] [Related]
11. Human antigen R mediated post-transcriptional regulation of inhibitors of apoptosis proteins in pancreatic cancer.
Lukosiute-Urboniene A; Jasukaitiene A; Silkuniene G; Barauskas V; Gulbinas A; Dambrauskas Z
World J Gastroenterol; 2019 Jan; 25(2):205-219. PubMed ID: 30670910
[TBL] [Abstract][Full Text] [Related]
12. Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma.
Iakovlev V; Siegel ER; Tsao MS; Haun RS
Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1135-42. PubMed ID: 22573795
[TBL] [Abstract][Full Text] [Related]
13. KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Koga A; Sato N; Kohi S; Yabuki K; Cheng XB; Hisaoka M; Hirata K
Pancreatology; 2017; 17(1):115-122. PubMed ID: 28012880
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.
Xue Y; Abou Tayoun AN; Abo KM; Pipas JM; Gordon SR; Gardner TB; Barth RJ; Suriawinata AA; Tsongalis GJ
Cancer Genet; 2013 Jun; 206(6):217-21. PubMed ID: 23933230
[TBL] [Abstract][Full Text] [Related]
15. Presence of pancreatic intraepithelial neoplasia-3 in a background of chronic pancreatitis in pancreatic cancer patients.
Hwang IK; Kim H; Lee YS; Kim J; Cho JY; Yoon YS; Han HS; Hwang JH
Cancer Sci; 2015 Oct; 106(10):1408-13. PubMed ID: 26183380
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of MUC13 in pancreatic ductal adenocarcinoma.
Khan S; Zafar N; Khan SS; Setua S; Behrman SW; Stiles ZE; Yallapu MM; Sahay P; Ghimire H; Ise T; Nagata S; Wang L; Wan JY; Pradhan P; Jaggi M; Chauhan SC
HPB (Oxford); 2018 Jun; 20(6):563-572. PubMed ID: 29352660
[TBL] [Abstract][Full Text] [Related]
17. The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.
Yuan Y; Yang Z; Miao X; Li D; Liu Z; Zou Q
Tumour Biol; 2015 Dec; 36(12):9961-8. PubMed ID: 26178481
[TBL] [Abstract][Full Text] [Related]
18. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
[TBL] [Abstract][Full Text] [Related]
19. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
20. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
